Actively Recruiting
Loratadine to Prevent Bone Pain Caused by G-CSF During Stem Cell Transplant in Adults with Lymphoma or Multiple Myeloma
Led by AHS Cancer Control Alberta · Updated on 2026-02-05
78
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying whether loratadine can prevent or lessen bone pain caused by granulocyte colony stimulating factor G-CSF during autologous hematopoietic stem cell transplant in patients with lymphoma or multiple myeloma. The trial is a phase 2 study evaluating if loratadine is more effective than a placebo in this setting. The goal is to see if loratadine can reduce the severity of G-CSF-related bone pain in these patients. Participants will be randomly assigned to receive either loratadine 10 mg or a placebo capsule. The medication is started 3 hours before the first dose of G-CSF during the stem cell mobilization process and continued daily for at least 8 days. The study uses a triple-blind design to compare the effects of loratadine versus placebo. During the study, participants will complete pain assessments using the Brief Pain Inventory daily and the QLQ-BM22 questionnaire at the start and end of treatment up to 12 days. Researchers will also monitor stem cell mobilization effectiveness, time to stem cell re-engraftment, use of additional medications for pain and mobilization, and progression-free survival for one year after treatment. Participants adherence to the protocol and safety will be closely monitored throughout the study period.
CONDITIONS
Brief Title
Loratadine for the Prevention of G-CSF-related Bone Pain
Research Team
M
Michael Chu, MD
R
Rammy Khadour
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here